Baird Medical's MWA Technology Successfully Applied in Endocrine Procedures
Baird Medical Investment Holdings (NASDAQ: BDMD) has announced the successful implementation of its microwave ablation (MWA) technology in two endocrine procedures. The procedures were performed by Dr. Saka Kazeem, an endocrinologist with over 30 years of experience.
Dr. Kazeem, using the MWA system for the first time, commended its efficiency and seamless integration into clinical practice, noting its intuitive nature and optimization of procedure time without compromising patient outcomes. Chairwoman Haimei Wu emphasized the technology's value in improving clinical workflows and patient care.
The company has expressed its commitment to expanding its presence and collaborating with medical professionals to advance MWA technology applications.
Baird Medical Investment Holdings (NASDAQ: BDMD) ha annunciato l'implementazione con successo della sua tecnologia di ablazione a microonde (MWA) in due procedure endocrine. Le procedure sono state eseguite dal Dr. Saka Kazeem, un endocrinologo con oltre 30 anni di esperienza.
Il Dr. Kazeem, utilizzando il sistema MWA per la prima volta, ha lodato la sua efficienza e integrazione fluida nella pratica clinica, sottolineando la sua natura intuitiva e l'ottimizzazione dei tempi di procedura senza compromettere i risultati per i pazienti. La Presidente Haimei Wu ha enfatizzato il valore della tecnologia nel migliorare i flussi di lavoro clinici e la cura dei pazienti.
L'azienda ha espresso il suo impegno a espandere la propria presenza e collaborare con i professionisti medici per promuovere le applicazioni della tecnologia MWA.
Baird Medical Investment Holdings (NASDAQ: BDMD) ha anunciado la implementación exitosa de su tecnología de ablación por microondas (MWA) en dos procedimientos endocrinos. Los procedimientos fueron realizados por el Dr. Saka Kazeem, un endocrinólogo con más de 30 años de experiencia.
El Dr. Kazeem, utilizando el sistema MWA por primera vez, elogió su eficiencia y la integración fluida en la práctica clínica, destacando su naturaleza intuitiva y la optimización del tiempo del procedimiento sin comprometer los resultados para los pacientes. La Presidenta Haimei Wu enfatizó el valor de la tecnología para mejorar los flujos de trabajo clínicos y la atención al paciente.
La empresa ha expresado su compromiso de expandir su presencia y colaborar con profesionales médicos para avanzar en las aplicaciones de la tecnología MWA.
베어드 메디컬 인베스트먼트 홀딩스 (NASDAQ: BDMD)는 두 가지 내분비 절차에서 마이크로웨이브 절제(MWA) 기술의 성공적인 구현을 발표했습니다. 이 절차는 30년 이상의 경험을 가진 내분비학자 사카 카짐 박사에 의해 수행되었습니다.
카짐 박사는 MWA 시스템을 처음 사용하면서 그 효율성과 임상 실무에의 원활한 통합을 칭찬했으며, 직관적인 특성과 환자 결과를 저해하지 않으면서 절차 시간을 최적화한다고 언급했습니다. 회장 하이메이 우는 임상 작업 흐름과 환자 치료를 개선하는 데 있어 기술의 가치를 강조했습니다.
회사는 MWA 기술 응용을 발전시키기 위해 의료 전문가와 협력하고 존재감을 확장하겠다는 의지를 표명했습니다.
Baird Medical Investment Holdings (NASDAQ: BDMD) a annoncé la mise en œuvre réussie de sa technologie d'ablation par micro-ondes (MWA) dans deux procédures endocriniennes. Les procédures ont été réalisées par le Dr. Saka Kazeem, un endocrinologue avec plus de 30 ans d'expérience.
Le Dr. Kazeem, utilisant le système MWA pour la première fois, a salué son efficacité et son intégration fluide dans la pratique clinique, notant sa nature intuitive et l'optimisation du temps de procédure sans compromettre les résultats pour les patients. La Présidente Haimei Wu a souligné la valeur de la technologie pour améliorer les flux de travail cliniques et les soins aux patients.
L'entreprise a exprimé son engagement à étendre sa présence et à collaborer avec des professionnels de la santé pour faire avancer les applications de la technologie MWA.
Baird Medical Investment Holdings (NASDAQ: BDMD) hat die erfolgreiche Implementierung seiner Mikrowellenablationstechnologie (MWA) in zwei endokrinen Verfahren bekannt gegeben. Die Verfahren wurden von Dr. Saka Kazeem, einem Endokrinologen mit über 30 Jahren Erfahrung, durchgeführt.
Dr. Kazeem, der das MWA-System zum ersten Mal einsetzte, lobte dessen Effizienz und die nahtlose Integration in die klinische Praxis und hob dessen intuitive Natur sowie die Optimierung der Verfahrenszeit hervor, ohne die Patientenergebnisse zu beeinträchtigen. Vorsitzende Haimei Wu betonte den Wert der Technologie zur Verbesserung klinischer Arbeitsabläufe und der Patientenversorgung.
Das Unternehmen hat sein Engagement zum Ausdruck gebracht, seine Präsenz auszubauen und mit medizinischen Fachkräften zusammenzuarbeiten, um die Anwendungen der MWA-Technologie voranzutreiben.
- Successful clinical validation of MWA technology in endocrine procedures
- Positive feedback from experienced medical professional on system efficiency
- Technology demonstrates potential for procedure time optimization
- clinical evidence with only two procedures reported
- Early-stage market penetration with first-time usage by the physician
Using Baird Medical's MWA system for the first time, Dr. Kazeem praised its efficiency and seamless integration into clinical practice. "The system is both intuitive and optimizes procedure time, allowing treatments more streamlined without compromising patient outcomes," he stated.
Baird Medical remains dedicated to driving innovation in medical technology and promoting the adoption of MWA among healthcare professionals worldwide. "Dr. Kazeem's successful experience highlights the value of our technology in improving clinical workflows and patient care," said Haimei Wu, Chairwoman of Baird Medical. "We are excited to introduce our solutions to more physicians seeking effective, minimally invasive treatment options."
As the Company continues to expand its presence, Baird Medical is committed to collaborating with leading medical professionals and institutions to drive further innovation in microwave ablation technology and its applications.
About Baird Medical
Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of AI-powered surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company's technological roadmap will fully integrate breakthrough innovations from the open-source AI community—leveraging cutting-edge inference models such as Deepseek and Grok3, while fostering strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical has deployed its solutions in over 30 prestigious hospitals and clinics across
Forward-Looking Statements
This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.
Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in
The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medicals-mwa-technology-successfully-applied-in-endocrine-procedures-302415245.html
SOURCE BDMD
FAQ
What recent clinical milestone did Baird Medical (BDMD) achieve with its MWA technology?
How did Dr. Kazeem evaluate BDMD's microwave ablation system performance?
What are Baird Medical's (BDMD) future plans for its MWA technology?
When did Baird Medical (BDMD) announce its successful endocrine procedures?
